We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

The Effect of High Dose Salbutamol on Muscle Performance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01415596
Recruitment Status : Unknown
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was:  Active, not recruiting
First Posted : August 12, 2011
Last Update Posted : August 12, 2011
Information provided by:

August 11, 2011
August 12, 2011
August 12, 2011
August 2011
August 2012   (Final data collection date for primary outcome measure)
Muscle power
Same as current
No Changes Posted
Muscle recovery
Same as current
Not Provided
Not Provided
The Effect of High Dose Salbutamol on Muscle Performance
The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males
Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Ergogenic Effects of Salbutamol in Healthy Males
  • Drug: salbutamol
  • Drug: Placebo
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Salbutamol
    Intervention: Drug: salbutamol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
August 2013
August 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males
  • age 18-45
  • training frequency > 10 hrs/wk
  • informed consent

Exclusion Criteria:

  • smoker or former smoker
  • chronic diseases, as well as asthma
  • allergy to the study drugs
  • intake of any form of medicin or inhibited drugs during the study
  • use of beta2-agonist 14 days before the intervention
Sexes Eligible for Study: Male
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Vibeke Backer, Bispebjerg Hospital
Bispebjerg Hospital
University of Copenhagen
Not Provided
Bispebjerg Hospital
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP